CD8A and neoplasm: Under this adjusted context on tumor microenvironment, the ICIs treatment taken concurrently could successfully facilitate activation and infiltration of various anti-tumor immune cells such as CD8 T cells, DCs, and NK cells, and transform TAMs to an anti-tumor M1 macrophage phenotype.